Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2024-09-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, open-label, phase I/II basket study, evaluating the safety,
tolerability, RP2D, pharmacokinetics, pharmacodynamics and antitumor activity of EOS-448
combined with standard of care and/or with investigational therapies in participants with
advanced solid tumors.: EOS-448 will be combined with pembrolizumab, a marketed anti-PD-1
antibody in one treatment arm and a second treatment arm will evaluate EOS-448 combined with
inupadenant, an investigational adenosine A2A receptor antagonist.